Iressa vs Placebo as Maintenance Therapy in Locally Advanced NSCLC
A Phase III, Double-Blind, Randomised Study Comparing ZD1839 (IressaTM) Versus Placebo As Maintenance Therapy In Subjects With Locally Advanced Stage III Non-Small Cell Lung Cancer (NSCLC) After Combined Modality Therapy
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Avellino, Italy
- Research Site
-
Bergamo, Italy
- Research Site
-
Bologna, Italy
- Research Site
-
Cagliari, Italy
- Research Site
-
Campobasso, Italy
- Research Site
-
Catania, Italy
- Research Site
-
Catanzaro, Italy
- Research Site
-
Chieti, Italy
- Research Site
-
Cosenza, Italy
- Research Site
-
Della Fratte, Italy
- Research Site
-
Emilia, Italy
- Research Site
-
Fano, Italy
- Research Site
-
Firenze, Italy
- Research Site
-
Forli, Italy
- Research Site
-
Frattamaggiore, Italy
- Research Site
-
Livorno, Italy
- Research Site
-
Messina, Italy
- Research Site
-
Milano, Italy
- Research Site
-
Napoli, Italy
- Research Site
-
Novara, Italy
- Research Site
-
Orbassano, Italy
- Research Site
-
Padova, Italy
- Research Site
-
Palermo, Italy
- Research Site
-
Pavia, Italy
- Research Site
-
Potenza, Italy
- Research Site
-
Ravenna, Italy
- Research Site
-
Rimini, Italy
- Research Site
-
Roma, Italy
- Research Site
-
San Giovanni Rotondo, Italy
- Research Site
-
Sassari, Italy
- Research Site
-
Taormina, Italy
- Research Site
-
Venezia-Mestre, Italy
- Research Site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Histologically Confirmed Non Small Cell Lung Cancer.
- Locally advanced disease previously treated with combined therapy (chemotherapy and surgery with or without radiotherapy, or chemotherapy and radiotherapy).
- Chemotherapy with regimens containing cisplatin or carboplatin is mandatory
- Response to combined therapy
Exclusion Criteria:
- No previous treatment with ZD1839 or any other EGFR-targeted therapy
- No progressive disease after combined therapy for locally advanced NSCLC
- No presence of metastatic disease
- No other co-existing malignancies or malignancies diagnosed within the last 5 years with the exception of basal cell carcinoma or cervical cancer in situ
- Any unresolved chronic toxicity from previous anticancer therapy.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
|---|
|
Time to progression (2 years after Last patient in)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
|---|
|
Modalities of relapse or progression (2 years after Last patient in)
|
|
Overall survival (2 years after Last patient in)
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Lucio Crino, MD, Bologna Italy
Study record dates
Study Major Dates
Study Start
Study Start
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Neoplasms
- Lung Diseases
- Neoplasms by Site
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
- Lung Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Protein Kinase Inhibitors
- Gefitinib
Other Study ID Numbers
Other Study ID Numbers
- 1839IL/0126
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.